Avalo director granted options for 20,100 shares
Avalo Therapeutics director Kevin Robert Lind received a stock option grant covering 20,100 shares of Common Stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Avalo Therapeutics director Kevin Robert Lind received a stock option grant covering 20,100 shares of Common Stock. The option has an exercise price of $13.96 per share and expires on June 2, 2036. It vests 100% on the first anniversary of the grant date, subject to his continued board service. Following this award, he holds 20,100 derivative securities directly.
Insider Trade Summary
Grant/Award: 20,100 shares
Grant/Award
1 txn
Insider
Lind Kevin Robert
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 20,100 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 20,100 contracts (Direct)
Footnotes (1)
- F1. The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date.
Key Figures
Option shares granted: 20,100 shares
Exercise price: $13.96 per share
Expiration date: June 2, 2036
+1 more
4 metrics
Option shares granted
20,100 shares
Stock Option (Right to Buy) granted to director
Exercise price
$13.96 per share
Conversion or exercise price of stock option
Expiration date
June 2, 2036
Option expiration for director grant
Total derivative holdings after grant
20,100 options
Total shares following transaction
Key Terms
Stock Option (Right to Buy), exercise price, vests 100% on the first anniversary, expiration date, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 13.9600"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vests 100% on the first anniversary financial
"The stock option vests 100% on the first anniversary of the date of grant"
expiration date financial
"expiration_date: 2036-06-02T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Avalo Therapeutics (AVTX) director Kevin Robert Lind report on this Form 4?
Kevin Robert Lind reported receiving a stock option grant for 20,100 shares of Avalo Therapeutics Common Stock. The award is compensation, not an open-market trade, and gives him the right to buy shares at a fixed exercise price in the future.
What is the exercise price of Kevin Robert Lind’s Avalo Therapeutics stock option?
The exercise price of the stock option granted to Kevin Robert Lind is $13.96 per share. This price is the fixed cost at which he can purchase Avalo Therapeutics Common Stock if he chooses to exercise the option in the future.
When does Kevin Robert Lind’s Avalo Therapeutics stock option vest and become exercisable?
The stock option vests 100% on the first anniversary of the grant date. Vesting is conditioned on Lind’s continued service as a director on that vesting date, meaning he must remain on the board for the option to fully vest.
What is the expiration date of Kevin Robert Lind’s Avalo Therapeutics stock option?
The stock option issued to Kevin Robert Lind expires on June 2, 2036. After this expiration date, he will no longer have the right to exercise the option to purchase Avalo Therapeutics Common Stock at the stated exercise price.
Does this Avalo Therapeutics Form 4 show any stock bought or sold on the market?
This Form 4 shows a grant of a stock option, not an open-market purchase or sale. The transaction is classified as a grant or award acquisition, reflecting equity compensation rather than a discretionary trade in Avalo Therapeutics shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
